What Schools Are Affiliated With Daniel J. Sargent

Daniel J. Sargent is affiliated with the following schools: University of Pennsylvania, University of Leeds, MD Anderson Cancer Center, California Institute of Technology, McMaster University, Wayne State University, University of Modena and Reggio Emilia, Cardiff University, Mayo Clinic College of Medicine and Science, University of Siena, Duke University, Monash University, National University of Ireland, Hasselt University, McGill University, Vassar College, University of Portland, University of Hong Kong, Iowa State University, University of British Columbia, University of Minnesota, Stanford University, University of North Carolina at Chapel Hill

Daniel J. Sargent | Academic Influence

Daniel J. Sargent's AcademicInfluence.com Rankings

Daniel J. Sargent

Computer Science

#3998

World Rank

#4204

Historical Rank

Machine Learning

#659

World Rank

#669

Historical Rank

Artificial Intelligence

#861

World Rank

#877

Historical Rank

Database

#1242

World Rank

#1309

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Daniel J. Sargent's Degrees

Masters Artificial Intelligence Stanford University

Similar Degrees You Can Earn

Best Online Master's in Artificial Intelligence 2025

Why Is Daniel J. Sargent Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daniel J. Sargent's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009) (17488)
A comparison of laparoscopically assisted and open colectomy for colon cancer. (2004) (3239)
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. (2004) (2237)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. (2003) (2023)
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. (2010) (1318)
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. (2000) (1301)
Guidelines 2000 for colon and rectal cancer surgery. (2001) (1270)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) (1224)
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. (2009) (1176)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. (2004) (1055)
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial (2007) (1040)
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? (2004) (977)
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. (2001) (943)
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. (2015) (877)
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. (2002) (805)
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. (2010) (733)
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. (2002) (723)
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). (2008) (658)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. (2004) (632)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer (2018) (557)
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. (2009) (511)
Clinical trial designs for predictive marker validation in cancer treatment trials. (2005) (506)
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. (2005) (499)
Revised TN categorization for colon cancer based on national survival outcomes data. (2010) (497)
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. (2012) (480)
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. (2005) (476)
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. (2012) (457)
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. (2006) (447)
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. (2004) (421)
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. (2007) (415)
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. (2011) (399)
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. (1999) (382)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2016) (371)
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. (2009) (367)
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. (2014) (334)
Progression-free survival is a surrogate for survival in advanced colorectal cancer. (2007) (324)
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. (2015) (320)
Biomarkers and surrogate end points—the challenge of statistical validation (2010) (296)
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. (2008) (285)
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. (2015) (285)
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. (2009) (284)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. (2015) (281)
Curative Potential of Multimodality Therapy for Locally Recurrent Rectal Cancer (2003) (266)
Comparison of artificial neural networks with other statistical approaches (2001) (264)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. (2017) (260)
Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials (2011) (245)
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. (2005) (241)
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine (2016) (232)
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. (2013) (232)
Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer (2008) (231)
Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications (2012) (227)
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. (2006) (226)
Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia (2008) (225)
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. (2007) (223)
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. (2010) (223)
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. (2002) (220)
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial (2019) (217)
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. (2010) (216)
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. (2006) (215)
Prognostic factors in colorectal cancer (2009) (210)
Drug rechallenge and treatment beyond progression—implications for drug resistance (2013) (206)
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. (2013) (206)
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. (2001) (204)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer (2017) (196)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. (2016) (188)
Individual patient data analysis to assess modifications to the RECIST criteria. (2009) (180)
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. (2002) (179)
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. (2008) (178)
The radial distance of extraprostatic extension of prostate carcinoma (1999) (173)
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. (2011) (171)
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. (2008) (166)
Counting degrees of freedom in hierarchical and other richly-parameterised models (2001) (165)
Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors (2010) (162)
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. (2005) (160)
An adaptive dose‐finding design incorporating both toxicity and efficacy (2006) (159)
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. (2009) (156)
Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. (2002) (156)
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. (2001) (156)
Randomized Phase II Clinical Trials (2014) (150)
32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 (2008) (150)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee (2010) (145)
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. (2016) (145)
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. (2002) (143)
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. (2013) (142)
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. (2014) (142)
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy (2013) (138)
Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. (2012) (133)
Optimising the design of phase II oncology trials: the importance of randomisation. (2009) (131)
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance) (2014) (129)
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). (2014) (129)
Randomized Phase II Designs (2009) (126)
A general framework for random effects survival analysis in the Cox proportional hazards setting. (1998) (125)
Integrating biomarkers in clinical trials (2011) (125)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (121)
Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. (2016) (120)
Validation of novel imaging methodologies for use as cancer clinical trial end-points. (2009) (117)
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials (2008) (109)
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. (2014) (107)
Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. (1999) (106)
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. (2016) (106)
Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. (2010) (105)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All (2009) (104)
Lessons learned from independent central review. (2009) (101)
Current Issues in Adjuvant Treatment of Stage II Colon Cancer (2006) (100)
Population-based study of the contribution of weather to hip fracture seasonality. (1995) (98)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study (2017) (96)
Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas (2012) (95)
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. (2011) (95)
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. (2010) (95)
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. (2012) (94)
Method for evaluating prediction models that apply the results of randomized trials to individual patients (2007) (94)
Predictive biomarker validation in practice: lessons from real trials (2010) (94)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (94)
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials (2010) (90)
Swallow Function in Patients Before and After Intra‐Arterial Chemoradiation (2003) (90)
Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. (2015) (89)
Clinical implications of microsatellite instability in sporadic colon cancers (2009) (88)
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. (2004) (88)
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status (2009) (87)
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. (2011) (85)
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. (2017) (85)
Alternate Endpoints for Screening Phase II Studies (2009) (83)
Adaptive adjustment of the randomization ratio using historical control data (2013) (83)
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. (2015) (83)
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018) (82)
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas (2008) (82)
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials (2017) (82)
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. (2007) (81)
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials (2009) (80)
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. (2016) (80)
Assessing the measure of a new drug: is survival the only thing that matters? (2008) (79)
Refining multimodal therapy for rectal cancer. (2001) (79)
Randomized phase II trials: inevitable or inadvisable? (2010) (77)
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. (2016) (77)
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials (2017) (77)
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? (2006) (76)
A three-outcome design for phase II clinical trials. (2001) (75)
Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers (2006) (75)
Adjuvant therapy in the elderly: making the right decision. (2007) (75)
Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin (2004) (73)
Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (2014) (73)
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
A flexible design for multiple armed screening trials (2001) (73)
Cost implications of new treatments for advanced colorectal cancer (2009) (72)
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study (2017) (72)
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. (2009) (72)
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (2017) (71)
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. (2010) (70)
Contribution of Weather to the Seasonality of Distal Forearm Fractures: A Population-Based Study in Rochester, Minnesota (1999) (68)
Molecular Biomarkers for the Evaluation of Colorectal Cancer (2017) (68)
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. (2000) (68)
Issues in clinical trial design for tumor marker studies. (2002) (67)
End points in advanced colon cancer clinical trials: a review and proposal. (2007) (67)
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. (2013) (66)
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. (2003) (66)
Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. (1998) (65)
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 (2008) (65)
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. (2007) (65)
Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146) (2011) (64)
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations (2007) (64)
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. (2009) (63)
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) (2015) (63)
Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial. (2009) (62)
Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation (2005) (62)
Structured Markov Chain Monte Carlo (2000) (61)
pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013 (2003) (60)
Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups (2011) (58)
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 (2008) (58)
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. (2011) (57)
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. (2014) (57)
N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study (2004) (56)
Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147 (2010) (56)
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. (2009) (55)
A Flexible Approach to Time-varying Coefficients in the Cox Regression Setting (1997) (55)
Clinical trial designs incorporating predictive biomarkers. (2016) (53)
Randomized phase II trials: time for a new era in clinical trial design. (2010) (53)
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. (2011) (53)
Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. (2013) (53)
Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee (2014) (52)
Clinical Trial Designs for Prospective Validation of Biomarkers (2005) (51)
Multi‐state models for colon cancer recurrence and death with a cured fraction (2014) (49)
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. (2018) (49)
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. (2012) (48)
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. (2011) (48)
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. (2011) (48)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability (2006) (47)
Robust Bayesian approaches for clinical trial monitoring. (1996) (46)
Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study (2008) (46)
Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges (2010) (46)
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. (2017) (45)
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. (1997) (45)
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. (2010) (44)
Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial) (2014) (43)
5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. (2005) (42)
Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer (2009) (42)
Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma (2000) (41)
Cost‐effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first‐line therapy for metastatic colorectal carcinoma (2005) (41)
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. (2014) (41)
Blinded independent central review of the progression-free survival endpoint. (2010) (40)
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. (2006) (40)
Optimism bias leads to inconclusive results-an empirical study. (2011) (40)
Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers (2008) (40)
Genotype-based clinical trials in cardiovascular disease (2015) (39)
[Breast cancer in the early stage]. (2012) (39)
Statistical issues in tumor marker studies. (2000) (39)
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. (2005) (39)
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. (2014) (39)
Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses. (2005) (39)
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. (2010) (39)
Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma (2003) (38)
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. (2002) (38)
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. (2004) (38)
Systematic review of statistical methods used in molecular marker studies in cancer (2008) (38)
New treatment options for colorectal cancer. (2004) (38)
Lack of Caudal‐Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer (2017) (37)
3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) (2007) (37)
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia (2002) (36)
What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? (2010) (36)
Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. (2002) (36)
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes (2010) (35)
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. (2009) (35)
Survival is not a good outcome for randomized trials with effective subsequent therapies. (2011) (35)
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. (2009) (35)
Biomarkers, subgroup evaluation, and clinical trial design. (2012) (35)
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. (2009) (34)
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) (2016) (33)
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? (2007) (33)
Exploring racial differences in outcome and treatment for metastatic colorectal cancer (2012) (33)
Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) (2007) (32)
Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors (2014) (32)
Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. (2011) (32)
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. (2017) (32)
Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis (2011) (31)
Intraoperative radiotherapy for head and neck and skull base cancer (2003) (31)
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. (2013) (31)
The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. (2014) (31)
Surrogate endpoint validation: statistical elegance versus clinical relevance (2008) (31)
Definition of disease-free survival: this is my truth-show me yours. (2005) (31)
Smoothing Balanced Single-Error-Term Analysis of Variance (2007) (30)
Surgical Quality Surrogates Do Not Predict Colon Cancer Survival in the Setting of Technical Credentialing: A Report from the Prospective COST Trial (2013) (30)
Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials (2011) (30)
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. (2007) (30)
Surgeon Volume Does Not Predict Outcomes in the Setting of Technical Credentialing: Results From a Randomized Trial in Colon Cancer (2008) (30)
Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability (2007) (30)
Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity (2005) (30)
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. (2017) (30)
Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. (2000) (30)
A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. (2003) (30)
A pilot study of high‐dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tract (2005) (29)
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. (2014) (29)
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). (2017) (29)
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. (2016) (29)
Bayesian adjusted R2 for the meta‐analytic evaluation of surrogate time‐to‐event endpoints in clinical trials (2012) (28)
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? (2004) (28)
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. (2006) (28)
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). (2016) (27)
The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. (2015) (27)
FDG-PET lymphoma demonstration project invitational workshop. (2007) (27)
Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials (2011) (27)
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. (2012) (27)
A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer (2005) (26)
Exploring and validating surrogate endpoints in colorectal cancer (2008) (26)
Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. (2002) (26)
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. (2002) (26)
Design of clinical trials for biomarker research in oncology. (2011) (25)
Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study (2014) (25)
Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS) (2008) (25)
Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments (2011) (25)
Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. (2010) (25)
Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers (2013) (25)
General and statistical hierarchy of appropriate biologic endpoints. (2006) (25)
Prognostic web‐based models for stage II and III colon cancer (2011) (24)
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. (2005) (24)
Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit (2012) (24)
Adjuvant therapy for colon cancer--the pace quickens. (2005) (23)
Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling (2012) (22)
Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. (2010) (22)
All-comers versus enrichment design strategy in phase II trials. (2011) (22)
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials (2011) (22)
Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. (2016) (22)
Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology (2017) (22)
Prediction of radial distance of extraprostatic extension from pretherapy factors. (2007) (22)
Model‐based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients (2010) (21)
Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). (2004) (21)
Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology (2017) (20)
Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects. (2016) (20)
A review of phase II trial designs for initial marker validation. (2013) (20)
Current Issues in Oncology Drug Development, with a Focus on Phase II Trials (2009) (19)
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer (2005) (19)
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer (2009) (19)
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. (2011) (18)
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. (2015) (18)
Innovative estimation of survival using log-normal survival modelling on ACCENT database (2013) (18)
A north central cancer treatment group Phase II trial of 9‐aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma (2000) (18)
Clinical trials data collection: when less is more. (2010) (17)
Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time (2012) (17)
Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (2011) (17)
Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS) (2008) (17)
Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
Genomic advances and their impact on clinical trial design (2009) (17)
A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation (2012) (17)
Molecular diagnostics: assays, tissues, progress, and pitfalls. (2003) (17)
Causal Effects of Treatments for Informative Missing Data due to Progression/Death (2010) (16)
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. (2010) (16)
Current use and surgical efficacy of laparoscopic colectomy in colon cancer. (2013) (16)
Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis (2008) (16)
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU (2005) (16)
Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials (2012) (15)
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. (2009) (15)
On Bayesian methods of exploring qualitative interactions for targeted treatment (2012) (15)
A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC) (2007) (15)
Is En-Bloc Resection of Locally Recurrent Rectal Carcinoma Involving the Urinary Tract Indicated? (2006) (15)
Rapid reporting and review of an increased incidence of a known adverse event. (2000) (14)
Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147 (2016) (14)
A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer. (2006) (14)
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. (2014) (14)
NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. (2009) (14)
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. (2015) (14)
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. (2015) (14)
A Bayesian dose‐finding design incorporating toxicity data from multiple treatment cycles (2017) (14)
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. (2014) (13)
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. (2011) (13)
Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. (2006) (13)
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. (2014) (13)
Center-within-trial versus trial-level evaluation of surrogate endpoints (2014) (13)
Time to initiation of adjuvant chemotherapy and survival in colorectal cancer. (2011) (12)
Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy (2005) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance) (2018) (12)
New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study (2016) (12)
A new strategy for speeding Markov chain Monte Carlo algorithms (2003) (12)
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. (2018) (12)
Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. (2013) (12)
TN categorization for rectal and colon cancers based on national survival outcome data (2008) (11)
Sam Wieand, PhD (2006) (11)
Pick the winner designs in phase II cancer clinical trials. (2006) (11)
Disease-free survival in colon cancer: still relevant after all these years! (2013) (11)
Sample size and design considerations for phase II clinical trials with correlated observations. (1997) (11)
Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot (2002) (11)
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). (2018) (10)
Erratum: DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy (Journal of the National Cancer Institute (2011) 103:11 (863-875)) (2011) (10)
N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC) (2007) (10)
Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points (2015) (10)
N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. (2004) (10)
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. (2009) (10)
Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine. (2016) (10)
Final results of hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic (M-CRC) to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. (2004) (10)
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). (2017) (10)
Robust Bayesian design and analysis of clinical trials via prior partitioning (1996) (10)
Statistical considerations for the next generation of clinical trials. (2011) (10)
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials. (2015) (10)
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2018) (9)
Mining the ACCENT database: a review and update. (2013) (9)
Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. (2016) (9)
Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. (2009) (9)
The ARCAD advanced colorectal cancer database--open for business. (2012) (9)
The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis (2005) (9)
Decade in review—clinical trials: Shifting paradigms in cancer clinical trial design (2014) (9)
Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). (2017) (9)
Excessive false-positive errors in single-arm phase II trials: A simulation-based analysis. (2009) (9)
Endpoints for Colon Adjuvant Clinical Trials (CACT): Recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials (2005) (9)
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. (2011) (8)
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver: A North Central Cancer Treatment Group (NCCTG) phase II intergroup trial. (2006) (8)
Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study (2014) (8)
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data (2017) (8)
Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model (2015) (8)
Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint (2012) (8)
Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival (2011) (8)
Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials (2017) (8)
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. (2015) (7)
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. (2015) (7)
Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future (2010) (7)
Risk Models for Individualized Prognosis in the Practice of Precision Oncology (2017) (7)
The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program (2013) (7)
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107. (2006) (7)
Oncology clinical trials (2013) (7)
The radial distance of extraprostatic extension of prostatic adenocarcinoma: Implications for prostate brachytherapy (1998) (6)
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles (2018) (6)
New lessons from "old" chemotherapy in colorectal cancer. (2008) (6)
The ARCAD clinical trials program: an update and invitation. (2012) (6)
One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer. (2016) (6)
Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset (2007) (6)
SPECIAL ARTICLE Guidelines 2000 for Colon and Rectal Cancer Surgery (2001) (6)
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741 (2007) (6)
Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. (2013) (6)
Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. (2015) (6)
Calibration of quality-adjusted life years for oncology clinical trials. (2014) (6)
Rejoinder for “Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling” (2012) (6)
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. (2020) (6)
North Central Cancer Treatment Group--achievements and perspectives. (2008) (6)
The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project (2017) (6)
Direct cost-survival analysis of therapies for metastatic colorectal cancer. (2006) (6)
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. (2015) (6)
Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line (2008) (6)
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). (2015) (5)
Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. (2017) (5)
Overview: biostatistician's role in oncology clinical trials-strive for sound, efficient and practical studies. (2014) (5)
A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. (2016) (5)
Application of tumor measurement-based metrics in the real world. (2013) (5)
Relationship Between Metformin Use and Recurrence and Survival in Patients (PTS) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance). (2015) (5)
Adverse-event rates: journals versus databases (2007) (5)
Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts. (2014) (5)
Handbook of Statistics in Clinical Oncology, 2nd edition Edited by Crowley, J. and Ankerst, D. P. (2006) (5)
Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy. (2014) (5)
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. (2013) (5)
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. (2011) (5)
In reply [8] (2005) (5)
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. (2014) (5)
Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial. (2016) (5)
Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. (2015) (5)
Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC) (2007) (5)
Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC). (2016) (5)
Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. (2012) (5)
Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database. (2014) (4)
Biostatistics and bioinformatics (2012) (4)
Systemic Therapy for Elderly Patients with Gastrointestinal Cancer (2011) (4)
DRAFT FOR PUBLIC COMMENT Defining Clinically Meaningful Outcomes: ASCO Recommendations to Raise the Bar for Clinical Trials (2013) (4)
Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due. (2015) (4)
259 Patterns of failure after liver resectionin patients receiving FOLFOX4 for metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study (2003) (4)
Predictive and prognostic value of gender in early-stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database. (2011) (4)
A false‐discovery‐rate‐based loss framework for selection of interactions (2008) (4)
Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial. (2006) (4)
The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups (2015) (4)
Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741. (2004) (4)
Comparison of innovative estimation of efficacy to standard using the ACCENT database. (2011) (4)
Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study (2016) (4)
Predictive Biomarkers and Personalized Medicine Association Study of the let-7 miRNA-Complementary Site Variant in the 3 0 Untranslated Region of the KRAS Gene in Stage III Colon Cancer ( NCCTG N 0147 Clinical Trial ) (2014) (4)
Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. (2017) (4)
The ARCAD advanced colorectal cancer database-open for business. (2012) (4)
A GENERAL GIBBS SAMPLING ALGORITHM FOR ANALYZING LINEAR MODELS USING THE SAS SYSTEM (1999) (4)
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials (2019) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. (2016) (4)
LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) (2017) (4)
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. (2014) (3)
A phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): A clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) Study (2005) (3)
Meta-analysis of Individual-patient Survival Data Using Random-effect Models (2000) (3)
Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial. (2004) (3)
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance). (2017) (3)
Anti-angiogenic therapy for metastatic colorectal cancer (2007) (3)
Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. (2015) (3)
Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer (2014) (3)
Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. (2016) (3)
Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. (2018) (3)
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. (2010) (3)
Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP). (2014) (3)
Chemotherapy: Failure of bevacizumab in early-stage colon cancer (2011) (3)
Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (2014) (3)
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. (2016) (3)
Biomarkers-guided targeted drugs: New clinical trials design and practice necessity (2011) (2)
Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741 (2004) (2)
Reply to D.J. Stewart (2010) (2)
Lack of publication bias in randomized clinical trials (RCTs) sponsored by the National Cancer Institute (NCI) and performed by Cooperative Oncology Groups (COGs) (2004) (2)
Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin. (2015) (2)
Novel endpoints in phase III clinical trials. (2005) (2)
A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups (2018) (2)
Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group (2008) (2)
CRM Trials for Assessing Toxicity and Efficacy (2012) (2)
Comment on: ‘Evaluation of chemoresponse assays as predictive markers' (2015) (2)
SUGI 28: An Approach to Displaying Predicted Survival Data Based on the Level of a Continuous Covariate (2003) (2)
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. (2011) (2)
Elderly patients with metastatic esophageal/gastric cancer: A pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials (2008) (2)
611TiPADJUVANT REGORAFENIB (REG) IN STAGE IV COLORECTAL CANCER (CRC) AFTER CURATIVE TREATMENT OF LIVER METASTASES: A PHASE III RANDOMIZED, PLACEBO (PBO)-CONTROLLED TRIAL (COAST). (2014) (2)
Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients (2016) (2)
Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials (2016) (2)
Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset. (2010) (2)
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. (2011) (2)
A phase II trial design with direct assignment option for initial marker validation. (2012) (2)
Strategies for speeding Markov chain (2000) (2)
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2017) (2)
Role of Deficient DNAMismatch Repair Status in PatientsWith Stage III Colon Cancer Treated With FOLFOXAdjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials (2017) (2)
Sound footing or slippery slope? The value of secondary analyses of randomized trials. (2007) (2)
DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials. (2010) (2)
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC). (2010) (2)
CAIRO and FOCUS – Authors' reply (2007) (2)
New Adjuvant Trial Designs in Colon Cancer (2015) (2)
Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials. (2012) (2)
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). (2012) (2)
The components of progression as explanatory variables for overall survival in the RECIST database. (2012) (2)
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). (2014) (2)
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. (2014) (2)
753 Stool DNA Screening of Colorectal Neoplasia: Improved Adenoma Detection By Novel Digital Melt Curve Assay (2008) (2)
Key statistical concepts in cancer research. (2015) (2)
Evolving end points for clinical trials in advanced colorectal cancer (2009) (1)
Tumor burden is not related to quality of life in patients with metastatic colorectal cancer (2008) (1)
Statistics and Clinical Trials (2016) (1)
A phase II trial and quality-of-life analysis of a 5-day regimen of oral 5-fluorouracil bracketed by a 7-day regimen of oral eniluracil in untreated patients with unresectable or metastatic colorectal carcinoma (2002) (1)
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings (2008) (1)
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). (2015) (1)
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)--Findings from the ACCENT dataset. (2010) (1)
Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT). (2010) (1)
O-021Analysis of DNA mismatch repair and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials (2015) (1)
Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (2011) (1)
Reply to M.A. Rosen et al (2010) (1)
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). (2009) (1)
Choice of Endpoints in Cancer Clinical Trials (2018) (1)
Adjuvant treatment of stage II colon cancer: yes or no, what, when and why? (2013) (1)
Multitrial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse. (2013) (1)
Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration (2014) (1)
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance) (2018) (1)
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. (2016) (1)
New lesions versus growth of existing disease: Does it impact prognosis? (2011) (1)
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials. (2016) (1)
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials. (2019) (1)
Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database. (2017) (1)
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. (2009) (1)
Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts. (2012) (1)
DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer (2005) (1)
Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG) (2007) (1)
TITLE: A two-stage phase II design with direct assignment option in stage II for initial marker validation (2012) (1)
Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) (2008) (1)
Tu1518 Smoking Adversely Affects Colon Cancer Survival and Relapse Rates (2013) (1)
Cost-effectiveness projections of FOLFOX vs. IFL in first-line therapy of metastatic colorectal cancer in the context of the U.S. health care system (2005) (1)
Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database. (2011) (1)
O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
Duffy-Santner Confidence Intervals for the Two-Stage Three-Outcome Design (2006) (1)
A phase II flexible screening design allowing for interim analysis and comparison with historical control. (2013) (1)
Alterations in cell proliferation and apoptosis in human colon cancers with microsatellite instability. (2006) (1)
Predictors of lymph node count in colon adenocarcinoma. (2010) (1)
Advances in defective mismatch repair colon cancer. (2008) (1)
Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). (2015) (1)
31 INVITED Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer (2007) (1)
GCC expression in lymph nodes (LNs) as a significant determinant of recurrence in stage II colon cancer (CC) patients (pts). (2011) (1)
Genomic classifiers in colon cancer - clinical utility. (2008) (1)
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials. (2010) (1)
Chapter 12 – Statistics and Clinical Trials (2012) (1)
Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. (2011) (1)
Heterogeneity in an individual patient data meta-analysis: contribution of random effect survival models (2001) (1)
Reply to S.A. Kesikli et al (2012) (1)
Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database. (2014) (1)
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver (2007) (1)
From isolated hypotheses to connected practical studies: statisticians' role in a seamless targeted therapy development. (2012) (1)
LBA-010Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). (2017) (1)
W1883 Low Intraepithelial CD3+/FOXP3+ Regulatory T-Cell Ratio Predicts Adverse Outcome in Human Colon Carcinomas (2009) (1)
A relationship between ethics of clinical trials and therapeutic advances in cancer (2005) (0)
157 INVITED Cross-over in Oncology Clinical Trials – Statistical Issues (2011) (0)
Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). (2013) (0)
Improving Clinical Trials in the Era of Targeted Therapies (2014) (0)
Abstract B111: Obesity is associated with worse outcome in colon cancer survivors (2010) (0)
Phase III Clinical Trials with Anticancer Agents (2011) (0)
Independent central review of progression in randomized phase II/III oncology trials: Is it needed? (2011) (0)
Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. (2009) (0)
Detecting deficient DNA mismatch repair in stage II and III colon cancers. (2011) (0)
Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147. (2016) (0)
High dose intra-arterial cisplatin with concomitant accelerated radiotherapy for patients with T4 and selected T3, N0-3, M0 head and neck cancer. (2004) (0)
Molecular Markers, Molecular Signatures and Treatment Decision in Stage II Colon Cancer. (2013) (0)
Prognostication using molecular (mol) markers and clinicopathological (clpath) features in high-risk stage II/III colon cancer (CC). (2016) (0)
Careers in statistics: Getting a job: What distinguishes you? (2010) (0)
Impact of TNM stage on survival and disease control in adjuvant rectal cancer pooled analysis (2001) (0)
Reply to F. Montagnani et al (2009) (0)
Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers (2008) (0)
Association of Cytotoxic CD8+ Lymphocytes With Mismatch Repair Status and Patient Survival in Human Colon Carcinomas (2011) (0)
Adverse event (AE) assessment lists for clinical trials (CTs) influence AE reporting rates: An evaluation of AE data collected on North Central Cancer Treatment Group CTs (2007) (0)
PCN45 ECONOMIC ANALYSIS OF THE CLINICAL OUTCOMES OF SURGICAL THERAPY (COST) TRIAL COMPARING LAPAROSCOPICALLY-ASSISTED COLECTOMY (LAC) WITH OPEN COLECTOMY (OC) FOR COLON CANCER (2008) (0)
Reply to Verlingue, Koscielny and Ferté. (2014) (0)
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. (2011) (0)
Abstract 5102: Telomeres and survival in stage III colon cancers: Findings from NCCTG N0147 (Alliance) study (2014) (0)
Clinical Validation of Biomarkers (2013) (0)
Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer (2010) (0)
This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B (2019) (0)
Microsatellite instability but not thymidylate synthase is a prognostic variable in primary colon cancers from patients treated in 5-FU-based adjuvant studies. (2006) (0)
Reply to C.D. Atkins (2010) (0)
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators. (2009) (0)
Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLT). (2017) (0)
Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database. (2016) (0)
The value of preliminary data in power specifications based upon 64 NCCTG phase II/III treatment trials (2008) (0)
S1931 Colon Cancers With Defective DNA Mismatch Repair Show Reduced Recurrence, Delayed Time-to-Recurrence and Fewer Distant Metastases (2010) (0)
Activated EGFR as a prognostic marker in human colon cancer (2008) (0)
Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database. (2017) (0)
Efficacy a nd Q uality-of-Life D ata A re R elated i n a P hase I I Trial o f O ral C hemotherapy i n P reviously U ntreated P atients With M etastatic C olorectal C arcinoma (2002) (0)
Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair. (2012) (0)
Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database. (2016) (0)
Testing of evaluation bias for progression free survival endpoint in oncology clinical trials (2016) (0)
Clinical trial designs incorporating predictive biomarkers q (2016) (0)
Challenges to accrual predictions to phase III cancer clinical trials: A survey of study chairs and lead statisticians of 248 NCI-sponsored trials. (2009) (0)
Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. (2011) (0)
Clinical Validation of Biomarkers in Cancer (2010) (0)
Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase III (P3) overall survival (OS) outcomes using the RECIST 1.1 database. (2014) (0)
Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models Edited by Vittinghoff, E., Glidden, D. V., Shiboski, S. C., and Mcculloch, C. E (2006) (0)
Sargent Prognostic , Predictive , and Therapeutic Implications Molecular Pathways : Microsatellite Instability in Colorectal Cancer : Updated (2012) (0)
Further Evaluating the Benefi to f Adjuvant Chemotherapy for Colon (2016) (0)
Introduction to special issue on biomarker-based clinical trial designs in oncology. (2015) (0)
The IDEA Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX Regimen for Patients with Stage III Colon Cancer: Current Status. (2014) (0)
Colorectal cancer and evidence for cure by adjuvant chemotherapy (2009) (0)
The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer (2003) (0)
Prognostic impact of body mass index upon cancer recurrence and survival in stage III colon cancer patients from adjuvant chemotherapy trials. (2009) (0)
How many new treatments are "breakthroughs"? Evaluation of innovations in cancer (2005) (0)
Colorectal cancer-multimodality management: Edited by Len Saltz. 872 pp. $195.00. Totowa, New Jersey, Humana Press, 2002. ISBN 0-86903-935-8. Web address for ordering: www.humanapress.com (2003) (0)
Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741 (2008) (0)
Impact o f S urgical a nd P athologic V ariables i n R ectal Cancer: A U nited S tates C ommunity a nd C ooperative Group R eport (2001) (0)
Baseline quality of life as a prognostic factor for overall survival in lung cancer patients. (2009) (0)
S2036 Pro-Apoptotic Bad and Bid Protein Expression Predict Survival in Stage II and III Colon Cancer Patients (2008) (0)
Abstract 4112: Prognostic impact of autophagic markers LC3, Beclin 1 and p62/sequestosome 1 in colon carcinomas from patients treated in 5-FU-based adjuvant therapy trials (2012) (0)
O-009Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials (2015) (0)
Reply to P. Prassopoulos et al (2010) (0)
Randomization in the presence of historical controls (2012) (0)
Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients. (2015) (0)
Abstract 1151:cMYCamplification in colon cancer: A novel association withBRAFV600E and proficient DNA mismatch repair: (2012) (0)
Economic analysis of the Clinical Outcomes of Surgical Therapy (COST) trial comparing laparoscopically-assisted colectomy (LAC) with open colectomy (OC) for colon cancer (2008) (0)
Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database. (2015) (0)
Evaluation of Alternate Tumor Metrics and Cut-Points for Response Categorization Using the RECIST 1.1 Data Warehouse (2012) (0)
Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities (2014) (0)
S1963 Colon Cancers with Defective DNA Mismatch Repair Show Delayed Time-to-Recurrence and Differences in Patterns of Metastatic Spread (2009) (0)
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. (2012) (0)
Randomized Phase IIDesigns (2009) (0)
Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147. (2012) (0)
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance). (2013) (0)
6009 Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (2009) (0)
Abstract C53: Dose‐finding designs for combination therapies involving molecularly targeted agents (2009) (0)
Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis: Section I: Methods and Framework (2007) (0)
Lack of publication bias in randomized clinical trials (RCTs) sponsored by the National Cancer Institute (NCI) and performed by Cooperative Oncology Groups (COGs). (2004) (0)
Epidermal growth factor receptor expression correlates with histologic grade but not microsatellite instability in primary colon carcinomas. (2006) (0)
Smaller, faster trials: The right way to assess new targeted agents? A simulation study. (2011) (0)
Using disease-free survival as an alternate endpoint in colorectal cancer patients: Commentary (2006) (0)
Long-term Outcome of Hepatitis C Virus Superinfection in HBsAg Carriers (2004) (0)
CORRECTION: Robust Bayesian Approaches for Clinical Trial Monitoring, by Bradley P. Carlin and Daniel J. Sargent, Statistics in Medicine, 15, 1093–1106 (1996) (1997) (0)
Is disease-free survival an appropriate primary end point for adjuvant colon cancer studies? (2006) (0)
Statistical methods frequently used in cancer research (1999) (0)
yetanotherchangetotheseventhAmericanJointCancerCommittee/ UnionInternationaleContreleCancerwillgreatlyimproveourability to provide better care. Then again, we hope that molecular predictors of disease velocity and treatment response will provide better staging, optimistically in the foreseeable futu (2012) (0)
Importance of randomization in early clinical trials. (2009) (0)
CDX2 loss as a prognostic and predictive biomarker in metastatic colorectal cancer (2016) (0)
Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC). (2013) (0)
Association study of the let-7 microRNA-binding site polymorphism in 3'-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. (2012) (0)
In reply [15] (2005) (0)
Reply to M. Chao et al (2009) (0)
Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis. (2012) (0)
EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas (2007) (0)
LBA14MOLECULAR SUBTYPE AND CHEMOTHERAPY-RELATED TOXICITY IN STAGE 3 COLON CANCERS: NCCTG N0147 (2014) (0)
134 POSTER An adaptive phase I design for identifying a dose-outcome region for two drug combinations (2006) (0)
Stool DNA testing for colorectal cancer shows promise (2008) (0)
Reply to I.D. Nagtegaal et al (2010) (0)
Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. (2017) (0)
Equipoise principle and NCI-sponsored clinical trials: Are investigators truly uncertain about their comparisons? (2005) (0)
Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers (2007) (0)
1206 ORAL Smaller, Faster Phase III Trials – New Approach for Assessing Targeted Agents? (2011) (0)

This paper list is powered by the following services:

Daniel J. Sargent

Daniel J. Sargent's Academic­Influence.com Rankings

Daniel J. Sargent's Degrees

Similar Degrees You Can Earn

Why Is Daniel J. Sargent Influential?

Daniel J. Sargent's Published Works

Published Works

What Schools Are Affiliated With Daniel J. Sargent?

Daniel J. Sargent's AcademicInfluence.com Rankings